This Article Full Text Full Text (PDF) Additional Materials All Versions of this Article: 28/5/961    most recent ATVBAHA.107.156596v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Leong, T. PubMed PubMed Citation Articles by Leong, T.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:961.)
© 2008 American Heart Association, Inc.

Clinical and Population Studies

Asymmetric Dimethylarginine Independently Predicts Fatal and Nonfatal Myocardial Infarction and Stroke in Women

24-Year Follow-Up of the Population Study of Women in Gothenburg

Tora Leong; Dimitri Zylberstein; Ian Graham; Lauren Lissner; Deirdre Ward; Jane Fogarty; Calle Bengtsson; Cecilia Björkelund; Dag Thelle for The Swedish-Irish-Norwegian (SIN) Collaboration

From the Department of Cardiology (T.L., I.G., D.W.), Adelaide & Meath Hospital, Tallaght, Dublin, Ireland; the Department of Public Health and Community Medicine (D.Z., L.L., C. Bengtsson, C. Björkelund, D.T.), Institute of Medicine at the Sahlgrenska Academy, Göteborg University, Göteborg, Sweden; the Department of Clinical Chemistry (J.F.), Adelaide & Meath Hospital, Tallaght, Dublin, Ireland; and the University of Oslo (D.T.), Oslo, Norway.

Correspondence to Prof Ian Graham, Department of Cardiology, Adelaide & Meath Hospital, Tallaght, Dublin 24, Ireland. E-mail ian.graham{at}amnch.ie

Abstract

Objective— Asymmetrical dimethylarginine (ADMA) reduces nitric oxide by inhibiting nitric oxide synthase is associated with cardiovascular disease (CVD). Our study examined the association of ADMA with CVD prospectively in a healthy population-based cohort of women.

Methods and Results— We measured baseline ADMA of 880 women in the Population Study of Women in Gothenburg using high-performance liquid chromatography. After adjustment for traditional risk factors, creatinine clearance, and homocysteine using Cox models, the HR (95% CI in parentheses) of CVD end points at 24 years for a 0.15 µmol/L (1 SD) increase in ADMA were: all-cause mortality 1.12 (0.96, 1.32), fatal CVD 1.30 (1.04, 1.62), total CVD events 1.29 (1.09, 1.53). The top quintile (ADMA 0.71 µmol/L) compared with the bottom four-fifths, conferred a cumulative risk 22 versus 14%, relative risk 1.75 (95% CI 1.18, 2.59) and population attributable risk 12.7% of total CVD events, and further identified individuals who are at higher than expected risk based on the SCORE and Framingham systems.

Conclusions— A 0.15 µmol/L increase in baseline ADMA levels is associated with approximately 30% increase in incident cardiovascular risk at 24 years in women after adjustment. ADMA levels 0.71 µmol/L enhances CVD risk assessment in women.

Baseline ADMA in the Population Study of Women in Gothenburg was associated with approximately 30% increase (adjusted) in incident cardiovascular events per 0.15 µmol/L (1 SD) increase in ADMA after 24 years of follow-up. ADMA 0.71 µmol/L can enhance both the SCORE and Framingham systems of cardiovascular risk assessment.

Key Words: asymmetrical dimethylarginine • cardiovascular diseases • myocardial infarction • stroke • women